41 61 688 11 11
Industry: Drug Manufacturers—General
Full-time employees: 103,613
|Dr. Severin Schwan Ph.D.||Exec. Chairman||7.51M||N/A||1967|
|Dr. Thomas Schinecker||Chief Exec. Officer||3.87M||N/A||1975|
|Dr. Alan Hippe||Chief Financial & Information Officer||4.11M||N/A||1967|
|Ms. Cristina A. Wilbur||Chief People Officer||2.92M||N/A||1967|
|Dr. Johannes Carolus Clevers M.D., Ph.D.||Head of Roche Pharma Research & Early Devel.||82.5k||N/A||1957|
|Dr. Bruno Eschli||Head of Investor Relations||N/A||N/A||N/A|
|Ms. Claudia Bockstiegel||Gen. Counsel||N/A||N/A||1964|
|Ms. Pascale Schmidt||Chief Compliance Officer||N/A||N/A||1973|
|Ms. Barbara Schadler||Head of Group Communications||N/A||N/A||1962|
|Dr. Nicolas Dunant||Head of Group Media Relations||N/A||N/A||N/A|
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
Roche Holding AG’s ISS governance QualityScore as of 1 June 2023 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 6; Compensation: 8.